Cutaneous T-Cell Lymphoma clinical trials at UC Irvine

• A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

  Sorry, in progress, not accepting new patients

  The purpose of this trial is to assess the efficacy of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL) in Stage I - III participants as assessed by objective response rate (ORR). A lead-in dose-finding part was used to determine dose level 9 microgram per kilogram (mcg/kg) E7777 that is being used to test efficacy and safety.

  Orange, California and other locations

• Mogamulizumab Q4week Dosing in Participants With R/R CTCL

  Sorry, not currently recruiting here

  This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.

  Irvine, California and other locations

Last updated: October 21, 2021